Find Aripiprazole Lauroxil manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

FDF DossiersDRUG PRODUCT COMPOSITIONS

14RELATED EXCIPIENT COMPANIES

30EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1259305-29-7, Aristada, Rdc-3317, Alks 9072, Aristada initio, Aripiprazole lauroxil [usan]
Molecular Formula
C36H51Cl2N3O4
Molecular Weight
660.7  g/mol
InChI Key
DDINXHAORAAYAD-UHFFFAOYSA-N
FDA UNII
B786J7A343

Aripiprazole Lauroxil
Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors. Affecting about 1% of the adult population in the United States and approximately 26 million people worldwide, schizophrenia is a chronic neurological disorder that may result in impairments in cognition and executive functions. The quality of life in patients is greatly reduced due to negative health outcomes, and oftentimes the patients are faced with social stigma and discriminations. Schizophrenia is characterized by positive symptoms such as delusions, hallucinations, thought disorders, and catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of emotional responses. D2 receptors have been the most common target for antipsychotic agents used in the treatment of schizophrenia: the positive symptoms are thought to arise from overactivity in the mesolimbic dopaminergic pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating. In a randomized, double-blind clinical trial, treatment of aripiprazole lauroxil in adult patients with schizophrenia resulted in improvement of positive and negative symptoms scores at day 85 of treatment. Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. It is administered via intramuscular injection, and requires the establishment of tolerability prior to dosing in treatment-nave patients. On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose. The patients may receive Aristada Initio in combination with a single 30 mg oral dose of aripiprazole to achieve appropriate levels of aripiprazole more rapidly. Long-acting injectable aripiprazole lauroxil displayed comparable efficacy and safety to aripiprazole, and reduced dosing frequency improves patient adherence.
1 2D Structure

Aripiprazole Lauroxil

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydroquinolin-1-yl]methyl dodecanoate
2.1.2 InChI
InChI=1S/C36H51Cl2N3O4/c1-2-3-4-5-6-7-8-9-10-16-35(43)45-28-41-33-27-30(19-17-29(33)18-20-34(41)42)44-26-12-11-21-39-22-24-40(25-23-39)32-15-13-14-31(37)36(32)38/h13-15,17,19,27H,2-12,16,18,20-26,28H2,1H3
2.1.3 InChI Key
DDINXHAORAAYAD-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCCCCCCCCCC(=O)OCN1C(=O)CCC2=C1C=C(C=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl
2.2 Other Identifiers
2.2.1 UNII
B786J7A343
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Aristada

2.3.2 Depositor-Supplied Synonyms

1. 1259305-29-7

2. Aristada

3. Rdc-3317

4. Alks 9072

5. Aristada Initio

6. Aripiprazole Lauroxil [usan]

7. Alks 9070

8. Rdc 3317

9. [7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-2-oxo-3,4-dihydroquinolin-1-yl]methyl Dodecanoate

10. Alks-9070

11. Alks-9072

12. Rdc3317

13. B786j7a343

14. Aripiprazole Lauroxil (usan)

15. Dodecanoic Acid, (7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2-oxo-1(2h)-quinolinyl)methyl Ester

16. (7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2h)-yl)methyl Dodecanoate

17. Unii-b786j7a343

18. Aristada (tn)

19. [7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2h)-yl]methyl Dodecanoate

20. Aripiprazole-lauroxil

21. Aripiprazol- Lauroxil

22. Schembl1044330

23. Chembl2219425

24. Chebi:90930

25. Dtxsid60154997

26. Aripiprazole Lauroxil [mi]

27. Bcp14993

28. Ex-a4069

29. Mfcd26967976

30. Zinc95564895

31. Aripiprazole Lauroxil [who-dd]

32. Db14185

33. Ncgc00532501-01

34. Ac-36504

35. As-35241

36. Aripiprazole Lauroxil [orange Book]

37. Hy-108751

38. Cs-0030962

39. D10364

40. A856290

41. Q25323757

42. Dodecanoic Acid [7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2-oxo-1(2h)-quinolinyl]methyl Ester

2.4 Create Date
2011-01-10
3 Chemical and Physical Properties
Molecular Weight 660.7 g/mol
Molecular Formula C36H51Cl2N3O4
XLogP310
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count6
Rotatable Bond Count20
Exact Mass659.3256625 g/mol
Monoisotopic Mass659.3256625 g/mol
Topological Polar Surface Area62.3 Ų
Heavy Atom Count45
Formal Charge0
Complexity858
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Aripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Aripiprazole, which is a major pharmacological metabolite of aripiprazole lauroxil, serves to improve the positive and negative symptoms of schizophrenia by modulating dopaminergic signalling pathways. Aripiprazole lauroxil is reported to have minimal effects on sexual function or prolactin levels.


5.2 MeSH Pharmacological Classification

Antipsychotic Agents

Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)


5.3 Absorption, Distribution and Excretion

Absorption

Following a single extended-release intramuscular injection of aripiprazole lauroxil, aripiprazole can be detected in the systemic circulation from 5 to 6 days and is continued to be released for an additional 36 days. The concentrations of aripiprazole increases with consecutive doses of aripiprazole lauroxil and the steady state is reached following the fourth monthly injection. The systemic exposure to aripiprazole was similar when comparing deltoid and gluteal intramuscular injections.


Route of Elimination

Based on the pharmacokinetic study for aripiprazole, less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.


Volume of Distribution

Based on population pharmacokinetic analysis, the apparent volume of distribution of aripiprazole following intramuscular injection of aripiprazole lauroxil was 268 L, indicating extensive extravascular distribution following absorption. Health human volunteer study indicates that aripiprazole crosses the blood-brain barrier.


Clearance

In rats, the clearance for aripiprazole lauroxil was 0.32 0.11 L/h/kg following injection of aripiprazole lauroxil molar equivalent to 5 mg aripiprazole/kg.


5.4 Metabolism/Metabolites

Aripiprazole lauroxil is hydrolyzed to form N-hydroxymethyl-aripiprazole via esterases. N-hydroxymethyl-aripiprazole undergoes a rapid, nonenzymatic spontaneous cleavage, or water-mediated hydrolysis, to form aripiprazole, which mainly contributes to the pharmacological actions of aripiprazole lauroxil. Aripiprazole is further metabolized by hepatic CYP3A4 and CYP2D6 to form dehydro-aripiprazole, which retains some pharmacological activity. Dehydro-aripiprazole displays affinities for D2 receptors similar to aripiprazole and represents 30-40% of the aripiprazole exposure in plasma. Cytochrome P450 2D6 is subject to genetic polymorphism, which results in pharmacokinetic differences among CYP2D6 metabolizer phenotypes and dosage adjustments accordingly.


5.5 Biological Half-Life

The mean aripiprazole terminal elimination half-life ranged from 29.2 days to 34.9 days after every 4-week injection of aripiprazole lauroxil 441, 662 and 882 mg.


5.6 Mechanism of Action

The pharmacological activity of aripiprazole lauroxil is thought to be mainly mediated by its metabolite aripiprazole, and to a lesser extent, dehydro-aripiprazole. Aripiprazole functions as a partial agonist at the dopamine D2 and the serotonin 5-HT1A receptors, and as an antagonist at the serotonin 5-HT2A receptor. The desired outcome of antipsuchotic agents in schizophrenia is to inhibit dopaminergic transmission in the limbic system and enhance dopaminergic transmission in the prefrontal cortex. As a partial agonist at D2 receptors in the mesolimbic dopaminergic pathway, aripiprazole acts as a functional antagonist in the mesolimbic dopamine pathway and reduces the extent of dopaminergic pathway activity. This results in reduced positive symptoms in schizophrenia and extrapyramidal motor side effects. In contrast, aripiprazole is thought to act as a functional agonist in the mesocortical pathway, where reduced dopamine activity is seen in association with negative symptoms and cognitive impairment. Antagonism at 5-HT2A receptors by aripiprazole alleviates the negative symptoms and cognitive impairment of schizophrenia. 5-HT2A receptors are Gi/Go-coupled that upon activation, produce neuronal inhibition via decreased neuronal excitability and decreased transmitter release at the nerve terminals. In the nigrostriatal pathway, 5-HT2A regulates the release of dopamine. Through antagonism of 5-HT2A receptors, aripiprazole disinhibits the release of dopamine in the striatum and enhance the levels of the transmitters at the nerve terminals. The combined effects of D2 and 5-HT2A antagonism are thought to counteract the increased dopamine function causing increased extrapyramidal side effects. Blocking 5-HT2A receptors may also lead to the modulation of glutamate release in the mesocortical circuit, which is a transmitter that plays a role in schizophrenia. 5-HT1A receptors are autoreceptors that inhibit 5-HT release upon activation. Aripiprazole is a partial agonist at theses receptors and reduces 5-HT release; this results in potentiated dopamine release in the striatum and prefrontal cortex. It is reported that therapeutic doses of aripiprazole occupies up to 90% of brain D2 receptors in a dose-dependent manner. Apripiprazole targets different receptors that lead to drug-related adverse reactions; for example, the antagonist activity at the alpha-1 adrenergic receptors results in orthostatic hypotension. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug.


API SUPPLIERS

read-more
read-more

01

Interquim SA

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothInterquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Flag Spain
Digital Content Digital Content
USDMF arrow-down Click Us! arrow-down
CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Interquim

02

Neuland Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothNeuland Laboratories- A dedicated 100% API provider.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF ASMF arrow-down AUDIT arrow-down
Neuland

03

Pharmathen SA

Greece

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Pharmathen

04

Honour Lab Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Company Banner

05

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

MSN Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

06

GLAND PHARMA LIMITED

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

GLAND PHARMA LIMITED

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

07

Cambrex Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Cambrex Corporation

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank

08

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

Zydus Lifesciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1650220200,"product":"ARIPIPRAZOLE LAUROXIL (TAX INV NO:290021","address":"MSN HOUSE ,PLOT NO. C-24, INDUSTRIAL ESTATE,SANATHNAGAR,HYDER","city":"HYDERABAD","supplier":"MSN PHARMACHEM PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"HAMBURG - FUHLSBUETT","customer":"NETZSCH FEINMAHLTECHNIK GMBHAL IND","customerCountry":"GERMANY","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"50000","totalValueFC":"4864.2","currency":"USD","unitRateINR":3670000,"date":"18-Apr-2022","totalValueINR":"367000","totalValueInUsd":"4864.2","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"9754580","productDescription":"API","marketType":"REGULATED MARKET","country":"GERMANY","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE ,PLOT NO. C-24, INDUSTRIAL ESTATE,SANATHNAGAR,HYDER, HYDERABAD","customerAddress":""}]
18-Apr-2022
18-Apr-2022
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Abilify (aripiprazole) action includes a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. It is approved by USFDA for the treatment of schizophrenia and for bipolar I disorder in adults.


Lead Product(s): Aripiprazole,Aripiprazole Lauroxil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Abilify Asimtufii

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Otsuka Holdings

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 28, 2023

blank

01

H. Lundbeck AS

Denmark
arrow
BIO Partnering at JPM
Not Confirmed

H. Lundbeck AS

Denmark
arrow
BIO Partnering at JPM
Not Confirmed

Details : Abilify (aripiprazole) action includes a combination of partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors. It is approved by USFDA for the treatment of schizophrenia and for bipolar I disorder in adults.

Product Name : Abilify Asimtufii

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 28, 2023

blank
  • Development Update

Details:

Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.


Lead Product(s): Aripiprazole Lauroxil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Alkermes Plc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 22, 2022

blank

02

University of Miami

Country
arrow
BIO Partnering at JPM
Not Confirmed

University of Miami

Country
arrow
BIO Partnering at JPM
Not Confirmed

Details : Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 22, 2022

blank

Details:

The objective of the randomized, double-blind, placebo-controlled, multicenter study is to determine if high-dose Octagam® 10% therapy will slow or stop respiratory deterioration in patients with severe coronavirus disease.


Lead Product(s): Aripiprazole Lauroxil,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Aristada Initio

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 20, 2020

blank

03

Octapharma

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Octapharma

Switzerland
arrow
BIO Partnering at JPM
Not Confirmed

Details : The objective of the randomized, double-blind, placebo-controlled, multicenter study is to determine if high-dose Octagam® 10% therapy will slow or stop respiratory deterioration in patients with severe coronavirus disease.

Product Name : Aristada Initio

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 20, 2020

blank

Details:

Results from the study provide evidence to support the use of the ARISTADA INITIO one-day regimen together with ARISTADA for treatment of an acute exacerbation of schizophrenia, started in the hospital setting and continued through the critical transition to outpatient care.


Lead Product(s): Aripiprazole Lauroxil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 20, 2020

blank

04

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Details : Results from the study provide evidence to support the use of the ARISTADA INITIO one-day regimen together with ARISTADA for treatment of an acute exacerbation of schizophrenia, started in the hospital setting and continued through the critical transitio...

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 20, 2020

blank
  • Development Update

Details:

Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.


Lead Product(s): Aripiprazole Lauroxil,Al-Ncd

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Alkermes Plc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 18, 2019

blank

05

University of California, Los Angeles

Country
arrow
BIO Partnering at JPM
Not Confirmed

University of California, Los Angeles

Country
arrow
BIO Partnering at JPM
Not Confirmed

Details : Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 18, 2019

blank

Details:

Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Schizophrenia.


Lead Product(s): Aripiprazole Lauroxil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 17, 2017

blank

06

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Details : Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Schizophrenia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 17, 2017

blank

Details:

Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.


Lead Product(s): Aripiprazole Lauroxil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 22, 2015

blank

07

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Details : Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 22, 2015

blank

Details:

Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.


Lead Product(s): Aripiprazole Lauroxil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 18, 2015

blank

08

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Details : Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Schizophrenia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 18, 2015

blank

Details:

Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.


Lead Product(s): Aripiprazole Lauroxil,Inapplicable

Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 19, 2014

blank

09

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

Details : Aripiprazole Lauroxil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Schizophrenia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 19, 2014

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Regulatory Info : USA

Registration Country : Greece

Aripiprazole Lauroxil

Brand Name :

Dosage Form : Long Acting Injectable

Dosage Strength : 441MG/SYRINGE

Packaging :

Approval Date :

Application Number :

Regulatory Info : USA

Registration Country : Greece

Pharmathen

02

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Regulatory Info : USA

Registration Country : Greece

Aripiprazole Lauroxil

Brand Name :

Dosage Form : Long Acting Injectable

Dosage Strength : 662MG/SYRINGE

Packaging :

Approval Date :

Application Number :

Regulatory Info : USA

Registration Country : Greece

Pharmathen

03

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Regulatory Info : USA

Registration Country : Greece

Aripiprazole Lauroxil

Brand Name :

Dosage Form : Long Acting Injectable

Dosage Strength : 882MG/SYRINGE

Packaging :

Approval Date :

Application Number :

Regulatory Info : USA

Registration Country : Greece

Pharmathen

04

Pharmathen SA

Greece
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothPharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.

Flag Greece
Digital Content Digital Content

Regulatory Info : USA

Registration Country : Greece

Aripiprazole Lauroxil

Brand Name :

Dosage Form : Long Acting Injectable

Dosage Strength : 1064MG/SYRINGE

Packaging :

Approval Date :

Application Number :

Regulatory Info : USA

Registration Country : Greece

Pharmathen

05

Alkermes Plc

Ireland
BIO Partnering at JPM
Not Confirmed
arrow

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

Brand Name : ARISTADA

Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Dosage Strength : 441MG/1.6ML (275.63MG/ML)

Packaging :

Approval Date : 2015-10-05

Application Number : 207533

Regulatory Info : RX

Registration Country : USA

blank

06

Alkermes Plc

Ireland
BIO Partnering at JPM
Not Confirmed
arrow

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

Brand Name : ARISTADA

Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Dosage Strength : 662MG/2.4ML (275.83MG/ML)

Packaging :

Approval Date : 2015-10-05

Application Number : 207533

Regulatory Info : RX

Registration Country : USA

blank

07

Alkermes Plc

Ireland
BIO Partnering at JPM
Not Confirmed
arrow

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

Brand Name : ARISTADA

Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Dosage Strength : 882MG/3.2ML (275.63MG/ML)

Packaging :

Approval Date : 2015-10-05

Application Number : 207533

Regulatory Info : RX

Registration Country : USA

blank

08

Alkermes Plc

Ireland
BIO Partnering at JPM
Not Confirmed
arrow

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

Brand Name : ARISTADA

Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Dosage Strength : 1064MG/3.9ML (272.82MG/ML)

Packaging :

Approval Date : 2017-06-05

Application Number : 207533

Regulatory Info : RX

Registration Country : USA

blank

09

Alkermes Plc

Ireland
BIO Partnering at JPM
Not Confirmed
arrow

Alkermes Plc

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

Brand Name : ARISTADA INITIO KIT

Dosage Form : SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Dosage Strength : 675MG/2.4ML (281.25MG/ML)

Packaging :

Approval Date : 2018-06-29

Application Number : 209830

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMU...DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 1064MG/3.9ML (272.82MG/ML)

USFDA APPLICATION NUMBER - 207533

read-more

DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMU...DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 441MG/1.6ML (275.63MG/ML)

USFDA APPLICATION NUMBER - 207533

read-more

DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMU...DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 662MG/2.4ML (275.83MG/ML)

USFDA APPLICATION NUMBER - 207533

read-more

DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMU...DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 882MG/3.2ML (275.63MG/ML)

USFDA APPLICATION NUMBER - 207533

read-more

DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMU...DOSAGE - SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR - 675MG/2.4ML (281.25MG/ML)

USFDA APPLICATION NUMBER - 209830

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

Solubilizers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Emulsifying Agents

read-more
read-more

Topical

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil

Drug Cost (USD) : 272,878,291

Year : 2023

Prescribers : 13295

Prescriptions : 90583

blank

02

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil,Submicr.

Drug Cost (USD) : 3,295,869

Year : 2023

Prescribers : 1249

Prescriptions : 1362

blank

03

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil

Drug Cost (USD) : 256,918,832

Year : 2022

Prescribers : 13161

Prescriptions : 88507

blank

04

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil,Submicr.

Drug Cost (USD) : 2,947,809

Year : 2022

Prescribers : 1173

Prescriptions : 1273

blank

05

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil

Drug Cost (USD) : 230,380,653

Year : 2021

Prescribers : 12813

Prescriptions : 82292

blank

06

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil,Submicr.

Drug Cost (USD) : 3,236,337

Year : 2021

Prescribers : 1332

Prescriptions : 1443

blank

07

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil

Drug Cost (USD) : 203,135,527

Year : 2020

Prescribers : 11836

Prescriptions : 76175

blank

08

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil,Submicr.

Drug Cost (USD) : 2,491,372

Year : 2020

Prescribers : 1067

Prescriptions : 1163

blank

09

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil

Drug Cost (USD) : 160,454,398

Year : 2019

Prescribers : 10998

Prescriptions : 64816

blank

10

arrow
Biotech Showcase
Not Confirmed
arrow
Biotech Showcase
Not Confirmed

Company : Alkermes Inc

Aripiprazole Lauroxil,Submicr.

Drug Cost (USD) : 2,246,756

Year : 2019

Prescribers : 1056

Prescriptions : 1106

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 11273158

Drug Substance Claim :

Drug Product Claim :

Application Number : 207533

Patent Use Code : U-543

Delist Requested :

Patent Use Description : TREATMENT OF SCHIZOPHR...

Patent Expiration Date : 2039-04-06

blank

02

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 9034867

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 207533

Patent Use Code : U-543

Delist Requested :

Patent Use Description : TREATMENT OF SCHIZOPHR...

Patent Expiration Date : 2032-11-07

blank

03

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 12311027

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 207533

Patent Use Code : U-543

Delist Requested :

Patent Use Description : TREATMENT OF SCHIZOPHR...

Patent Expiration Date : 2033-09-19

blank

04

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 12311027

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 207533

Patent Use Code : U-543

Delist Requested :

Patent Use Description : TREATMENT OF SCHIZOPHR...

Patent Expiration Date : 2033-09-19

blank

05

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 10813928

Drug Substance Claim :

Drug Product Claim :

Application Number : 207533

Patent Use Code : U-2983

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-03-19

blank

06

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 10813928

Drug Substance Claim :

Drug Product Claim :

Application Number : 207533

Patent Use Code : U-2983

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-03-19

blank

07

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 10112903

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 207533

Patent Use Code : U-543

Delist Requested :

Patent Use Description : TREATMENT OF SCHIZOPHR...

Patent Expiration Date : 2030-06-24

blank

08

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 10112903

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 209830

Patent Use Code : U-543

Delist Requested :

Patent Use Description : TREATMENT OF SCHIZOPHR...

Patent Expiration Date : 2030-06-24

blank

09

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 8796276

Drug Substance Claim :

Drug Product Claim :

Application Number : 207533

Patent Use Code : U-543

Delist Requested :

Patent Use Description : TREATMENT OF SCHIZOPHR...

Patent Expiration Date : 2030-06-24

blank

10

arrow
BIO Partnering at JPM
Not Confirmed

ALKERMES INC

Ireland
arrow
BIO Partnering at JPM
Not Confirmed

ARIPIPRAZOLE LAUROXIL

US Patent Number : 9193685

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 207533

Patent Use Code : U-543

Delist Requested :

Patent Use Description : TREATMENT OF SCHIZOPHR...

Patent Expiration Date : 2033-10-24

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ANALYTICAL

Upload your methods for free, ask us

ABOUT THIS PAGE

Looking for 1259305-29-7 / Aripiprazole Lauroxil API manufacturers, exporters & distributors?

Aripiprazole Lauroxil manufacturers, exporters & distributors 1

53

PharmaCompass offers a list of Aripiprazole Lauroxil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Aripiprazole Lauroxil manufacturer or Aripiprazole Lauroxil supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aripiprazole Lauroxil manufacturer or Aripiprazole Lauroxil supplier.

PharmaCompass also assists you with knowing the Aripiprazole Lauroxil API Price utilized in the formulation of products. Aripiprazole Lauroxil API Price is not always fixed or binding as the Aripiprazole Lauroxil Price is obtained through a variety of data sources. The Aripiprazole Lauroxil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Aripiprazole Lauroxil

Synonyms

1259305-29-7, Aristada, Rdc-3317, Alks 9072, Aristada initio, Aripiprazole lauroxil [usan]

Cas Number

1259305-29-7

Unique Ingredient Identifier (UNII)

B786J7A343

About Aripiprazole Lauroxil

Aripiprazole lauroxil is a long-acting injectable atypical antipsychotic drug used in the treatment of schizophrenia in adult patients. It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors. Affecting about 1% of the adult population in the United States and approximately 26 million people worldwide, schizophrenia is a chronic neurological disorder that may result in impairments in cognition and executive functions. The quality of life in patients is greatly reduced due to negative health outcomes, and oftentimes the patients are faced with social stigma and discriminations. Schizophrenia is characterized by positive symptoms such as delusions, hallucinations, thought disorders, and catanoia, and negative symptoms that include social withdrawal, anhedonia, and flattening of emotional responses. D2 receptors have been the most common target for antipsychotic agents used in the treatment of schizophrenia: the positive symptoms are thought to arise from overactivity in the mesolimbic dopaminergic pathway activating D2 receptors, whereas negative symptoms may result from a decreased activity in the mesocortical dopaminergic pathway with D1 receptors predominating. In a randomized, double-blind clinical trial, treatment of aripiprazole lauroxil in adult patients with schizophrenia resulted in improvement of positive and negative symptoms scores at day 85 of treatment. Aripiprazole lauroxil was initially approved by the FDA in October 2015 under the market name Aristada for the treatment of schizophrenia. It is administered via intramuscular injection, and requires the establishment of tolerability prior to dosing in treatment-nave patients. On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose. The patients may receive Aristada Initio in combination with a single 30 mg oral dose of aripiprazole to achieve appropriate levels of aripiprazole more rapidly. Long-acting injectable aripiprazole lauroxil displayed comparable efficacy and safety to aripiprazole, and reduced dosing frequency improves patient adherence.

Aristada Manufacturers

A Aristada manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aristada, including repackagers and relabelers. The FDA regulates Aristada manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aristada API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Aristada manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Aristada Suppliers

A Aristada supplier is an individual or a company that provides Aristada active pharmaceutical ingredient (API) or Aristada finished formulations upon request. The Aristada suppliers may include Aristada API manufacturers, exporters, distributors and traders.

click here to find a list of Aristada suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Aristada USDMF

A Aristada DMF (Drug Master File) is a document detailing the whole manufacturing process of Aristada active pharmaceutical ingredient (API) in detail. Different forms of Aristada DMFs exist exist since differing nations have different regulations, such as Aristada USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Aristada DMF submitted to regulatory agencies in the US is known as a USDMF. Aristada USDMF includes data on Aristada's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Aristada USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Aristada suppliers with USDMF on PharmaCompass.

Aristada NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aristada as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Aristada API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Aristada as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Aristada and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aristada NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Aristada suppliers with NDC on PharmaCompass.

Aristada GMP

Aristada Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Aristada GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aristada GMP manufacturer or Aristada GMP API supplier for your needs.

Aristada CoA

A Aristada CoA (Certificate of Analysis) is a formal document that attests to Aristada's compliance with Aristada specifications and serves as a tool for batch-level quality control.

Aristada CoA mostly includes findings from lab analyses of a specific batch. For each Aristada CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Aristada may be tested according to a variety of international standards, such as European Pharmacopoeia (Aristada EP), Aristada JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aristada USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty